We believe great partnerships create great possibilities and are inspired by our partners
As a global biopharmaceutical company, we leverage our agility, R&D capabilities and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease and Neuroscience. External innovation is at the heart of our strategy. We believe in the expertise of our partners and value the opportunity to collaborate, bringing our skills, experience and global reach to accelerate innovation to bring new medicines to patients.
Exclusively sourcing our pipeline through external innovation, we have no internal competing pipeline as we recognize the best science is delivered in biotech and academic institutions. We are proud our team comprises talents attracted from Pharma, biotech and academia, to drive shared success through creative collaborations.
Partnering with Ipsen
As a mid-size pharma, we leverage our agility, R&D capabilities and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease and Neuroscience. External innovation is at the heart of our strategy. We believe in the expertise of our partners and value the opportunity to collaborate, bringing our skills, experience and global reach to accelerate innovation to bring new medicines to patients.
A strong and solid mid-size pharmaceutical company delivering >€3bn sales in 2023 with growth across all regions.
We have now added >20 programs across every stage of development to Ipsen’s pipeline since 2021.
We now have 7 assets projected to deliver >500m sales by 2027, this was achieved together with our partners through accelerating, de-risking & maximizing these programs.
We intend to continue building this strong future for Ipsen through collaborations & acquisitions.
MARENGO CASE STUDY
Find out more about how we approach partnerships at Ipsen, where every program is a priority within our pipeline. We sat down with Zhen Su, CEO Marengo, to discuss our partnership and how we undertake a one team approach to accelerate innovation for the patients who are waiting.
Learn moreContact the partnering team
At Ipsen, entering partnerships is always personal. Our team is committed to success and has the expertise to deliver it. Contact us to see how together, we can accelerate innovation for patients.
PIPELINE
Exclusively building our pipeline through External Innovation
Our robust development pipeline, backed by our expertise and external-innovation strategy, supports patients’ health outcomes across Oncology, Rare Disease and Neuroscience.
Learn morePartnering events
Throughout the year, Ipsen holds numerous events for and with partners. Look through our upcoming events if you are interested in our work and in partnering with us and would like to meet our team.
Science-First Collaborations: Ipsen’s Blueprint to External Innovation
David Jenkins, SVP and Head of External Innovation and Research, leads efforts to identify, evaluate and secure new programs across Ipsen’s three strategic areas of Oncology, Rare disease, and Neuroscience. He shares his insights on the essential role that collaboration,…
Financial results for the first nine months of 2024
The financial results for the first half of the year will be published on July 25, 2024 at 7H00 and a conference call will take place at 13H00 CET.
Financial results for the first half of 2024
The financial results for the first half of the year will be published on July 25, 2024 at 7H00 and a conference call will take place at 13H00 CET.
Our 2023 Integrated Annual Report is live!
In 2023, we entered the next phase of our journey of growth and innovation, reinforcing our position as a leading mid-sized biopharmaceutical company. With a sharp focus on our three therapy areas of Oncology, Rare Diseases, and Neuroscience, we achieved total sales of €3,128 m.
Navigating Proactive Sustainability in Pharma R&D and Partnering
In March, we were proud to see Florence Dal Degan, Senior Director of External Innovation, participate in a panel discussion with different stakeholders, from consulting firms, pharma companies, investors to startups at BioEurope Spring entitled “Towards a Greener Globe: Biopharma’s Path to Sustaina
Q1 2024 sales update
The Q1 2024 sales announcement will be published on April 24, 2024 at 7am CET. Find out more and register for the conference call for investors and analysts.
Unlocking Potential Through Early-Stage Partnerships
We are pleased to share a recent conversation with Mary Jane Hinrichs, Senior Vice President, and Global Head of Early Development. Mary Jane spearheads the strategic direction and execution of early-stage programs at Ipsen, guiding them from drug candidate to…
Applications now open for the 2024 Golden Ticket competition
As part of our commitment to accelerating transformative research and development, we’re excited to announce that our annual Golden Ticket competition is now open! Through our continued partnership with BioLabs, we’re delighted to be offering the brightest minds in biotech…
Focus; Confidence; Commitment – The Building Blocks of Win-Win Partnerships
Ipsen’s Senior Director of Global Partnering for Oncology, Madee Gooriah, is part of the team leading efforts to expand Ipsen’s oncology franchise through external partnerships at every stage of development. But in an industry marked by complexity, how do we…
FY 2023 results announcement
Ipsen’s FY 2023 results announcement took place on 8 February 2024 at 7am CET/1am EST.